SEE-Tx® Platform
Download: SEE-Tx® Platform
Author: Roshan Ahmed
Getting Personal with Matthias Alder
What scientific innovation are you most excited about? Which innovation do you think will have the most impact in the next 20 years? I don’t
Behind the scenes of Gain Therapeutics COO: Matthias Alder
Your educational background is in law. What was the trajectory of your career? Well, it was an evolution. Throughout my career, I’ve always been involved
Conversations That Life Science Leaders Aren’t Having
Watch the full presentation video of Jeff Harman with Eric Richman, CEO of Gain Therapeutics: 00:01 I am Jeff Harmon 00:14 Eric Richman
Novel Allosteric Modulators: A Solution to Undruggable Targets – Jefferies 2022
Watch the full presentation video below : 0:00 Jefferies HealthCare Conference 0:24 Forward Looking Statement 0:40 Investment Highlights 02:49 Gain Therapeutics Two-Pronged Approach to Value
Is Computational Drug Discovery Finally Coming of Age ?
Piper Sandler recently published a comprehensive report entitled “Deciphering the Artificial Intelligence / Machine Learning Matrix Code in Biotech.” Why is this report significant? Technology
Oppenheimer Summit for Emerging Biotechnology (Montauk)
The Emerging Life Sciences Summit hosted by Oppenheimer will be on July 20th, 2022 in Montauk, NY. This yearly conference brings together the who’s who
Revolutionizing Drug Discovery for Previously “Undruggable” Genetically Defined Neurodegenerative Disease
“While we continue to see exciting advances across the biopharma innovation landscape, sadly, new approaches and therapies for neurodegenerative diseases continue to remain largely elusive
Conversations with Dr. Manolo Bellotto on Biotech Innovation, Protein Misfolding Diseases – Part II
Dr. Manolo Bellotto, General Manager and President of Gain Therapeutics, shares his personal story. You can follow him on : Twitter : @ManoloBellotto LinkedIn : https://www.linkedin.com/in/manolobellotto/
Conversations with Dr. Manolo Bellotto on Biotech Innovation, Protein Misfolding Diseases – Part I
We sat down and got a chance to speak with the General Manager and President of Gain Therapeutics, Dr. Manolo Bellotto. You can follow him
Gain Therapeutics at Jefferies Healthcare Conference 2022
Gain Therapeutics will be providing an update on our lead compound in development for GBA-associated Parkinson’s disease, GT-02287 at the Jefferies Global Healthcare Conference. Recent
Interview with Dr. Joanne Taylor on Neurodegenerative Research
1. What initially sparked your interest in neuroscience? Science has always interested me. Even as a young child I wanted to be a scientist or
PROTAC Technology: Advancing Protein Degradation Therapies
What is PROTAC? PROTAC, which is an acronym for proteolysis targeting chimera, is a class of heterobifunctional molecules that can be used to target specific proteins for degradation
Opportunities for Allosteric Therapeutics in Oncology
How do allosteric drugs compare to more traditional orthosteric drugs? Orthosteric drugs are compounds that bind to the active site of an enzyme. In order
The Relationship Between Prion Disease and Other Protein-Misfolding Diseases
What are prion diseases? Prion diseases are a group of neurodegenerative disorders that affect humans and other mammals. The most recognizable prion diseases are bovine
The Power of Supercomputing: Novel Allosteric Drug Discovery
The presentation by Professor Zoe Cournia, who is at the Biomedical Research Foundation Academy of Athens in Greece, was about the power of supercomputing and
STAR Compounds for GBA1-Associated Neurodegeneration in Gaucher & Parkinson’s Diseases
Professor Ricardo Feldman, who is from the University of Maryland School of Medicine, gave a presentation about Gain Therapeutics STAR molecules for the treatment of
The Role of Protein Misfolding in Neurodegenerative Diseases
Professor Tiago Outeiro who is Professor of Aggregopathies and Director of the Department of Experimental Neurodegeneration at the University Medical Center in Gottingen, Germany, and
STARs Technology: Gain Therapeutics’ Broad-Spectrum Solution for Misfolded Proteins
Presenting at Gain Therapeutics R&D Day, Manolo Bellotto, Ph. D elaborated on the Broad Application of Gain Therapeutics’ Structurally Targeted Allosteric Regulators (STARs). See the
How Big Data and Computation Drive Allosteric Target Discovery
Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about discovering Novel Allosteric Targets by Combining Advances in Big Data and Computational Technology.
Gain Therapeutics’ Small Molecule Approach for CNS diseases
Manolo Bellotto, Ph. D gave an overview of Gain Therapeutics GBA program during Gain Therapeutics R&D Day. He explained how GBA program targets beta-glucocerebrosidase, or
The Role of Allosteric Drug Discovery in Targeting Undruggable Proteins in Oncology
During Gain Therapeutics R&D Day, Samuel Broder, MD shares his perspective on Neuroscience and Beyond. The title of his presentation was “The Role of Allosteric
AlphaFold has modeled a high percentage of unknown protein structures: Dr. Xavier Barril
Q: Dr. Xavier Barril, what was the evolution of your career? A: I received my PhD in Biochemistry from the University of Barcelona in 2001
See-Tx applications for Protein Misfolding diseases
We have initially applied See-TX to selective protein misfolding diseases and have targeted lysosomal enzyme, to address the unmet medical needs of rare and neurodegenerative
Potential impact of Allosteric Drugs on Cancers, Neurodegenerative Diseases, and other serious diseases
What is allostery? Allo comes from the Greek allos which meaning “other.” Allosteric binding describes a ligand that binds a protein at a target site
Alzheimer’s Disease – Everything you need to know about it
When was Alzheimer’s disease discovered? Alzheimer’s disease as we know it was first described by Dr. Alois Alzheimer, a German doctor, in 1906. He was
The Role of Alpha-synuclein in Alzheimer’s Disease
Alpha-synuclein is a neuronal protein that regulates trafficking and neurotransmitter release. Aggregation of alpha-synuclein is associated with the formation of lewy bodies, which are protein
Leukodystrophy Therapy: How is Gain Therapeutics Developing First-in-class treatment for Krabbe Disease
Krabbe disease is a devastating disease that belongs to the Leukodystrophy disease family. These diseases are characterized by defects in the myelin, an insulating layer
Gaucher Disease & Parkinson’s: Understanding the Connection
Gaucher Disease and Parkinson’s Disease are two distinctly different diseases in terms of their onset, symptoms, and prognosis. Despite these differences these diseases have one
Gain Therapeutics: Revolutionary Drug Discovery with Physics, Biochem & Supercomputing
Discovering treatments for patients that currently have no available disease-modifying options is the priority of Gain Therapeutics. Specifically, there is a large unmet need for